As on January 20, 2021, Neos Therapeutics Inc. (NASDAQ: NEOS) got off with the flyer as it spiked 19.19% to $0.90. During the day, the stock rose to $1.10 and sunk to $0.76 before settling in for the price of $0.75 at the close. Taking a more long-term approach, NEOS posted a 52-week range of $0.45-$1.98.
It was noted that the giant of the Healthcare sector posted annual sales growth of 143.30% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 28.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 78.80%. This publicly-traded company’s shares outstanding now amounts to $49.76 million, simultaneously with a float of $49.01 million. The organization now has a market capitalization sitting at $45.96 million. At the time of writing, stock’s 50-day Moving Average stood at $0.6502, while the 200-day Moving Average is $0.6992.
It is quite fundamental to gauge the extent of the productivity of the business which is accounted for 213 workers. It has generated 303,516 per worker during the last fiscal year. Meanwhile, its income per employee was -79,352. The stock had 2.38 Receivables turnover and 0.64 Total Asset turnover. For the Profitability, stocks gross margin was +61.14, operating margin was -16.11 and Pretax Margin of -26.13.
Neos Therapeutics Inc. (NEOS) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Drug Manufacturers – Specialty & Generic industry. Neos Therapeutics Inc.’s current insider ownership accounts for 1.50%, in contrast to 33.40% institutional ownership.
Neos Therapeutics Inc. (NEOS) Earnings and Revenue Records
If we go through the results of last quarter, which was made public on 9/29/2020, the company posted -$0.1 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$0.05) by -$0.05. This company achieved a net margin of -26.14 while generating a return on equity of -1,971.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Neos Therapeutics Inc.’s EPS increase for this current 12-month fiscal period is 78.80% and is forecasted to reach -0.08 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 31.70% through the next 5 years, which can be compared against the 28.10% growth it accomplished over the previous five years trading on the market.
Neos Therapeutics Inc. (NASDAQ: NEOS) Trading Performance Indicators
Let’s observe the current performance indicators for Neos Therapeutics Inc. (NEOS). It’s Quick Ratio in the last reported quarter now stands at 0.50. The Stock has managed to achieve an average true range (ATR) of 0.09. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.81.
In the same vein, NEOS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.44, a figure that is expected to reach 0.00 in the next quarter, and analysts are predicting that it will be -0.08 at the market close of one year from today.
Technical Analysis of Neos Therapeutics Inc. (NEOS)
Through scrutinizing the latest numbers posted by the [Neos Therapeutics Inc., NEOS], it can be observed that its last 5-days Average volume of 9.09 million was better the volume of 5.88 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 51.80% While, its Average True Range was 0.0910.
Raw Stochastic average of Neos Therapeutics Inc. (NEOS) in the period of the previous 100 days is set at 59.73%, which indicates a major rise in contrast to 58.78% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 87.88% that was lower than 129.88% volatility it exhibited in the past 100-days period.